pRDA_429 Citations (2)
Originally described in: Benchmarking of SpCas9 variants enables deeper base editor screens of BRCA1 and BCL2.Sangree AK, Griffith AL, Szegletes ZM, Roy P, DeWeirdt PC, Hegde M, McGee AV, Hanna RE, Doench JG Nat Commun. 2022 Mar 14;13(1):1318. doi: 10.1038/s41467-022-28884-7. PubMed Journal
Articles Citing pRDA_429
| Articles |
|---|
Positive selection CRISPR screens reveal a druggable pocket in an oligosaccharyltransferase required for inflammatory signaling to NF-kappaB.
Lampson BL, Ramiotarez AS, Baro M, He L, Hegde M, Koduri V, Pfaff JL, Hanna RE, Kowal J, Shirole NH, He Y, Doench JG, Contessa JN, Locher KP, Kaelin WG Jr.
Cell. 2024 Apr 25;187(9):2209-2223.e16. doi: 10.1016/j.cell.2024.03.022.
PubMed
Associated Plasmids |
| Discovery of BMS-986408, a First-In-Class Dual DGKalpha and DGKzeta Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies. Wichroski M, Liu SQ, Zasadil LM, Benci JL, Gedeon PC, Condon KJ, Joshi S, Posy S, Carlson P, Maier A, Shen J, Kureshi R, Amako Y, Wang T, Powles RL, Li Y, Lai T, Katsyv I, Qiu H, Qi H, Wong J, Zhao D, Banas D, Onorato J, Locke G, Chen X, Chou WC, Cook E, Witt AE, Barbieri CM, Zhang H, Olsen JB, Font Tello A, Drokhlyansky E, Grunenfelder DC, Chupak L, Longmire TA, Jones JC, Hollmann TJ, Kugler DG, Feder JN, Bueno R, Wain J, Sivakumar P, Liu Y, Dougan SK, Paweletz CP, Barbie DA, Lees E. Cancer Immunol Res. 2025 Sep 2;13(9):1342-1362. doi: 10.1158/2326-6066.CIR-25-0156. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.